Stacie C. Lindsey is being recognized for her patient advocacy, alignment of research efforts and collaboration among the cancer community.
SALT LAKE CITY, UT - Cholangiocarcinoma Foundation CEO and Founder Stacie C. Lindsey has been named a finalist of the Cancer Community (C2) Awards in the category of C2 Catalyst Change. These awards recognize individuals and organizations who have created positive change in cancer care.
AstraZeneca and Scientific American Custom Media sponsor the awards that include nominations from organizations from across the cancer ecosystem and participation from an esteemed panel of third-party judges. Finalists are recognized by their peers for the inspiring work they do each day – all collectively working to make a difference for those living with and affected by cancer.
“It was an honor to be nominated for this prestigious award,” Lindsey said. “I am humbled to have been a finalist amongst this esteemed group of nominees.”
Lindsey’s brother, Mark Clements, was diagnosed with cholangiocarcinoma in 2005. He ultimately died from bile duct cancer on Jan. 19, 2007. Lindsey advocated for her brother, extensively researched treatment options, and began networking with other patients, researchers, and healthcare professionals. From this experience, the Cholangiocarcinoma Foundation was born and is celebrating its 15th anniversary this year.
Lindsey is a founding member of the Foundation and has served on the board of directors since its inception. She also serves on the steering committee of the Global Cholangiocarcinoma Alliance, the Program Steering Committee of the Cholangiocarcinoma Summit, and is a founding member of the organizing committee of the Asia Pacific Cholangiocarcinoma Conference. Furthermore, she is a patient advocate on both the Mayo Clinic Hepatobiliary SPORE and the Massachusetts General Hospital Hepatobiliary SPORE and serves as an executive committee member of the GI Cancers Alliance.
Lindsey serves as a founding member of the International Cholangiocarcinoma Research Network. This Network is a global consortium of researchers from more than 85 leading institutions working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis with an expectation to accelerate scientific and medical progress on an international level, expedite delivery of innovative care and treatments, and improve health outcomes for patients.
In addition to being a finalist for the C2 Catalyst for Change Award, Lindsey has received the 2020 Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, and the 2020 Public Service Award from the Society for Surgery of the Alimentary Tract. She resides in Herriman, Utah, where she is the mother of five children.
The C2 awards received more than 100 nominations in four categories:
C2 Catalyst for Change,
C2 Catalyst for Care,
C2 Catalyst for Precision Medicine,
Cholangiocarcinoma, pronounced (koh-LAN-jee-oh-KAR-sih-NOH-muh), is a highly lethal and rare bile duct cancer of the liver with a poor prognosis. With approximately 10,000 cases a year being diagnosed in the United States, cholangiocarcinoma is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization. Its mission is to find a cure and improve the quality of life for those affected by bile duct cancer. CCF supports basic & translational research and raises awareness in the cholangiocarcinoma community through advocacy, education, collaboration, and research. For more information, please visit our website at cholangiocarcinoma.org.